Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009

HIV Medicine

Volumn 6, Issue 6, 2005, Pages 410-420

  Boyd, Mark A ^a,b,f   Siangphoe, U ^a   Ruxrungtham, K ^a,c   Duncombe, C J ^a,b   Stek, M ^d   Lange, J M A ^a,e   Cooper, D A ^a,b   Phanuphak, P ^a,c  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d MERCK RESEARCH LABORATORIES   (United States)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Antiretroviral toxicity; Boosted protease inhibitor; Non nucleoside reverse transcriptase inhibitor; Nucleoside failure; Nucleoside sparing

Indexed keywords

ABACAVIR; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; BLOOD PRESSURE MONITORING; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG POTENCY; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY COLIC; LEUKOCYTE COUNT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL TOXICITY; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; PRIORITY JOURNAL; SIDE EFFECT; SKIN DEFECT; TREATMENT FAILURE; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

ADULT; AGED; ANTHROPOMETRY; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; CD4 LYMPHOCYTE COUNT; CREATININE; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INDINAVIR; LIPIDS; MALE; MIDDLE AGED; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 28444436183     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00327.x     Document Type: Article

References (27)

1. Yeni PG, Hammer SM, Hirsch MS et al. Treatment for Adult HIV Infection. 2004 Recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 2004; 2: 251-265.
2. Ruxrungtham K, Kroon ED, Ungsedhapand C et al. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients. AIDS 2000; 14: 1375-1382.
3. Ungsedhapand C, Kroon ED, Suwanagool S et al. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. J Acquir Immune Defic Syndr 2001; 27: 116-123.
4. Burger D, Boyd MA, Duncombe C et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir. J Antimicrob Chemother 2003; 51: 1231-1238.
5. Schambelan M, Benson C, Carr A et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr 2002; 31: 257-275.
6. Haas DW, Fessel WJ, Delapenha RA et al. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial. J Infect Dis 2001; 183: 392-400.
7. Albrecht AM, Bosch RJ, Hammer SM et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2000; 345: 398-407.
8. La Porte CJ, Wasmuth JC, Schneider K et al. Lopinavir/ritonavir plus saquinvir in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS 2003; 17: 1700-1702.
9. Stephan C, Hentig N, Kourbeti I et al. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 2004; 18: 503-508.
10. Boffito M, Kurowski M, Kruse G et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18: 1291-1297.
11. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
12. Boyd MA, Aarnoutse RE, Ruxrungtham K et al. The pharmacokinetics of indinavir/ritonavir 800/100 mg in combination with efavirenz: 600 mg in HIV-1 infected subjects. J Acquir Immune Defic Syndr 2003; 34: 134-139.
13. Shulman N, Zolopa AR, Passaro D et al. Phenotypic hypersensitivity to NNRT1 in treatment-experienced HIV-infected patients: impact on virological response to efavirenz based therapy. AIDS 2001; 15: 1125-1132.
14. Boyd MA, Duncombe CJ, Ruxrungtham K et al. Indinavir TID vs indinavir/ritonavir BID in combination with AZT/3TC for HIV infection in nucleoside pretreated patients: HIV-NAT 005 112 week follow-up. Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, February 2002 [Abstract 422-W].
15. Duvivier C, Myrto A, Marcelin AG et al. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals. Antivir Ther 2004; 8: 603-609.
16. Boyd M, Piroon M, Burger D et al. Pharmacokinetics of reduced-dosed indinavir/ritonavir 400/100 mg twice-daily in HIV-1 infected Thai patients. Antivir Ther 2005; 10: 301-307.
17. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein cholesterol as a protective factor against coronary artery disease. The Framingham Study. Am J Med 1977; 62: 707-714.
18. van Leth F, Hall D, Lange JMA, Reiss P. Increase in high-density lipoprotein cholesterol when using nevirapine and/or efavirenz is maintained up to 2 years. Program and Abstracts of the XV International AIDS Conference. Bangkok, Thailand, July 2004 [Abstract WePpB2065].
19. Grunfeld C, Pang M, Doerrler W et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74: 1045-1052.
20. Noor MA, Seneviratne T, Aweeka FT et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 29: F1-F8.
21. The DAD Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
22. Law MG, D'Arminio Monforte A, Friis-Moller N et al. Cardio and cerebrovascular events and predicted rates of myocardial infarction in the DAD study. Program and Abstracts of the 11th Conference on Refroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 737].
23. El-Sadr W, Reiss P, De Wit S et al. Relationship between prolonged exposure to combination ART and myocardial infarction: effect of sex, age, and lipid changes. Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 42].
24. Thiébaut R, El-Sadr W, Chenuc G et al. Predictors of hypertension and changes in blood pressure in HIV-infected patients in the DAD study. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 75].
25. Stamler J Blood pressure and high blood pressure. Aspects of risk. Hypertension 1991; 18: 95-107.
26. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16: 1341-1349.
27. Wasmuth JC, la Porte CJ, Schneider K, Burger DM, Rockstroh JK. Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR). Antivir Ther 2004; 9: 213-220.